Ernest P Kuchar, Joanna Chorostowska-Wynimko, L. Czupryniak, A. Fal, R. Flisiak, A. Mamcarz, A. Nitsch-Osuch, A. Skoczyńska, M. Stajszczyk, J. Wysocki, Michał Abendrot, D. Golicki, K. Jaśkowiak, Adam Antczak
{"title":"成人肺炎球菌疫苗接种——新机遇","authors":"Ernest P Kuchar, Joanna Chorostowska-Wynimko, L. Czupryniak, A. Fal, R. Flisiak, A. Mamcarz, A. Nitsch-Osuch, A. Skoczyńska, M. Stajszczyk, J. Wysocki, Michał Abendrot, D. Golicki, K. Jaśkowiak, Adam Antczak","doi":"10.5114/fmpcr.2023.125500","DOIUrl":null,"url":null,"abstract":"disease in adults and the vaccines used for prophylaxis for pneumococcal infection. the article discusses the pneumococcal infection burden in the adult population and the factors that raise the risk of infections. we characterised available vaccines for adults, highlighting the significant differences between the conjugated and unconjugated polysaccharide vaccines. Current epidemiological data on pneumococcal infections in europe and poland is presented. the latest 20-valent pneumococcal conjugate vaccine (pCV20) is described, and the most recent advisory Committee on immunization practices (aCip) recommendations on primary prevention and the current implementation of vaccination against pneumococcal infections in the adult population in poland are discussed.","PeriodicalId":305591,"journal":{"name":"Family Medicine & Primary Care Review","volume":"90 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Adult pneumococcal vaccination – new opportunities\",\"authors\":\"Ernest P Kuchar, Joanna Chorostowska-Wynimko, L. Czupryniak, A. Fal, R. Flisiak, A. Mamcarz, A. Nitsch-Osuch, A. Skoczyńska, M. Stajszczyk, J. Wysocki, Michał Abendrot, D. Golicki, K. Jaśkowiak, Adam Antczak\",\"doi\":\"10.5114/fmpcr.2023.125500\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"disease in adults and the vaccines used for prophylaxis for pneumococcal infection. the article discusses the pneumococcal infection burden in the adult population and the factors that raise the risk of infections. we characterised available vaccines for adults, highlighting the significant differences between the conjugated and unconjugated polysaccharide vaccines. Current epidemiological data on pneumococcal infections in europe and poland is presented. the latest 20-valent pneumococcal conjugate vaccine (pCV20) is described, and the most recent advisory Committee on immunization practices (aCip) recommendations on primary prevention and the current implementation of vaccination against pneumococcal infections in the adult population in poland are discussed.\",\"PeriodicalId\":305591,\"journal\":{\"name\":\"Family Medicine & Primary Care Review\",\"volume\":\"90 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Family Medicine & Primary Care Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5114/fmpcr.2023.125500\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Family Medicine & Primary Care Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/fmpcr.2023.125500","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Adult pneumococcal vaccination – new opportunities
disease in adults and the vaccines used for prophylaxis for pneumococcal infection. the article discusses the pneumococcal infection burden in the adult population and the factors that raise the risk of infections. we characterised available vaccines for adults, highlighting the significant differences between the conjugated and unconjugated polysaccharide vaccines. Current epidemiological data on pneumococcal infections in europe and poland is presented. the latest 20-valent pneumococcal conjugate vaccine (pCV20) is described, and the most recent advisory Committee on immunization practices (aCip) recommendations on primary prevention and the current implementation of vaccination against pneumococcal infections in the adult population in poland are discussed.